TIDMAMYT

RNS Number : 8035Y

Amryt Pharma PLC

08 March 2017

AIM: AMYT, ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")

Date of Results

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that results for the financial year to 31 December 2016 are expected to be reported on Thursday, 30 March 2017.

Enquiries:

 
                                   c/o KTZ Communications 
 Amryt Pharma plc                   +44 (0)20 3178 6378 
 Joe Wiley, CEO 
  Rory Nealon, CFO/COO 
 
 Shore Capital                     +44 (0) 20 7408 4090 
 Nomad and Joint Broker 
 Bidhi Bhoma, Edward Mansfield 
 
 Davy                              +353 (1) 679 6363 
 ESM Adviser and Joint Broker 
 John Frain, Anthony Farrell 
 
 Stifel                            +44 (0) 20 7710 7600 
 Joint Broker 
 Jonathan Senior, Ben Maddison 
 KTZ Communications                +44 (0) 20 3178 6378 
 Katie Tzouliadis, Emma Pearson

About Amryt Pharma plc - see www.amrytpharma.com

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.

Amryt's lead development product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company is currently planning a Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation. The global market opportunity for EB is estimated to be circa EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORSSEEFWFWSELD

(END) Dow Jones Newswires

March 08, 2017 02:01 ET (07:01 GMT)

Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Amryt Pharma Charts.
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Amryt Pharma Charts.